NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 55 resultados LastUpdate Última actualización 14/11/2018 [14:03:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR

NºPublicación: US2018319806A1 08/11/2018

Solicitante:
PHARMACYCLICS LLC [US]

Resumen de: US2018319806A1

Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.



traducir


 

METHOD FOR TREATING LEUKEMIA USING REPROGRAMMING EFFECT

NºPublicación: EP3398613A1 07/11/2018

Solicitante:
INST OF HEMATOLOGY AND BLOOD DISEASE HOSPITAL CHINESE ACADEMY OF MEDICAL SCIENCES AND PEKING UNION M [CN]

Resumen de: EP3398613A1

The present invention provides a method for treating leukemia using reprogramming factors Oct-4, Sox-2, Klf4 and c-Myc (OSKM for short).



traducir


 

SUBSTITUTED 2-METHYLIDENE-5-(PHENYLAMINO)-2,3-DIHYDROTHIOPHEN-3-ONES FOR TREATMENT OF LEUKEMIAS WITH TRANSLOCATIONS OF THE MLL GENE AND OTHER ONCOLOGICAL DISEASES

NºPublicación: WO2018199797A1 01/11/2018

Solicitante:
LLC ONCOTARTIS [RU]

Resumen de: WO2018199797A1

The invention relates to the chemistry of organic compounds, pharmacology and medicine, and concerns the prevention and/or treatment of hyperproliferative diseases associated with the malignant transformation of cells expressing the enzyme carboxylesterase hCE1, and specifically, acute leukemias with translocations of the MLL gene, hepatocellular carcinomas, and pulmonary adenocarcinomas. For this purpose, compounds of general formula (I), general formula (II), or general formula (III) are proposed in which R1, R2, A, B, and Q have values indicated in the description. The invention also relates to pharmaceutical compositions containing the indicated compounds, as well as to the use of the above-mentioned compounds for the treatment and/or prevention of hyperproliferative diseases.



traducir


 

BORIC ACID AND BORATE ESTER COMPOUND, AND PREPARATION METHOD AND USE THEREFOR

NºPublicación: WO2018196812A1 01/11/2018

Solicitante:
SELECTION BIOSCIENCE LLC [CN]

Resumen de: WO2018196812A1

Disclosed are a boric acid and borate ester compound, and a preparation method and use therefor. Specifically disclosed are a borate ester compound of formula I, a crystal form, and pharmaceutically acceptable salts, hydrates or solvates thereof, and a borate ester compound of formula II, a crystal form, and pharmaceutically acceptable salts, hydrates or solvates thereof. The boric acid and borate ester compound of the present invention have the function of inhibiting proteasome and can be used for treating multiple myeloma.



traducir


 

NOVEL DNMT INHIBITOR AS SOLID TUMOR THERAPEUTIC DRUG

NºPublicación: WO2018199049A1 01/11/2018

Solicitante:
OHARA PHARMACEUTICAL CO LTD [JP]

Resumen de: WO2018199049A1

[Problem] To provide, in place of injected agents (such as Vidaza (registered trademark) and Dacogen (registered trademark)) clinically used as therapeutic drugs for high-risk myelodysplastic syndromes, a medicine as a therapeutic drug or a prophylactic drug for various advanced solid tumors, said medicine having high stability with respect to cytidine deaminase which is a hydrolytic metabolic enzyme, being absorbed into the body even by oral administration, and having an effect of being integrated into a nucleic acid biosynthetic route and inhibiting DNA methyltransferases, i.e., DNMTs. [Solution] The aforementioned problem is solved by a novel compound represented by formula (I). (In the formula, R is a hydroxyl group or a hydrogen atom, and R1 and R2 are each a benzyl group that may have a substituent.)



traducir


 

TRIAZOLE BISPHOSPHONATE GERANYLGERANYL DIPHOSPHATE SYNTHASE INHIBITORS

NºPublicación: WO2018200603A1 01/11/2018

Solicitante:
UNIV NEBRASKA [US]
UNIV IOWA RES FOUND [US]

Resumen de: WO2018200603A1

Disclosed herein are inhibitors of the GGDPS enzyme, and methods for their use in treating or preventing diseases, such as multiple myeloma. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are described.



traducir


 

4-AMINOPYRIMIDINE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

NºPublicación: WO2018196757A1 01/11/2018

Solicitante:
UNIV CHINA PHARMA [CN]

Resumen de: WO2018196757A1

The present invention relates to the field of medicines, and specifically relates to a 4-aminopyrimidine compound having a structural feature represented by formula (I), or pharmaceutically acceptable salts thereof, a preparation method for the compound, and a use of the compound and the salts as a Bruton tyrosine kinase (BTK) inhibitor. A result of experiments shows that the compound in the present invention has a significant inhibition effect on the BTK, and can be used for treating thromboembolism, inflammatory disorders, autoimmune diseases, Waldenstrom macroglobulinemia, B cell lymphomas, and other diseases.



traducir


 

COMPOSITIONS AND METHODS FOR TREATING CANCER

NºPublicación: WO2018200931A1 01/11/2018

Solicitante:
UNIV OF VIRGINIA PATENT FOUNDATION [US]
UNIV BARCELONA [ES]
LOUGHRAN JR THOMAS P [US]
FABRIAS GEMMA [ES]
ABAD JOSE LUIS [ES]
CASAS JOSEFINA [ES]

Resumen de: WO2018200931A1

The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cell death of AML cells, and induce apoptosis in AML cells. A primary compound of the invention is SACLAC: 2-chloro-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide. The bromine analog of SACLAC (SABRAC: 2-bromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide) is also useful for treating AML. SACLAC has much better activity than other know drugs used to treat AML.



traducir


 

METHOD FOR TREATMENT AND PREVENTION OF BIOFILM FORMATION DURING BREAST AUGMENTATION PROCEDURES

NºPublicación: WO2018200739A1 01/11/2018

Solicitante:
INTEGRATED HEALING TECH LLC [US]

Resumen de: WO2018200739A1

The present disclosure provides methods and compositions for the treatment and prevention of infections and biofilm prevention during breast augmentation procedures. The present disclosure also provides methods and compositions for the prevention of anaplastic large-cell lymphoma following breast augmentation procedures. The present methods comprise providing a breast implant pocket at a surgical site in a patient and irrigating the pocket with a solution of hypochlorous acid. In some embodiments, the methods further comprise treating a breast implant with a solution of hypochlorous acid for a period of time prior to a breast augmentation procedure. Further provided are hypochlorous acid solutions useful in the aforementioned methods.



traducir


 

CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR

NºPublicación: WO2018201056A1 01/11/2018

Solicitante:
NOVARTIS AG [CH]
UNIV PENNSYLVANIA [US]

Resumen de: WO2018201056A1

The invention relates to the treatment of diseases associated with expression of BCMA, in particular myelomas. The invention relates to combination therapies of a BCMA CAR-expressing cell and a gamma secretase inhibitor.



traducir


 

ANTI-CD33 ANTIBODY AGENTS

NºPublicación: WO2018200562A1 01/11/2018

Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]

Resumen de: WO2018200562A1

Provided are anti-CD33 antibody agents, including anti-CD33 antibody agents in an IgG-scFv format. Various methods and reagents related thereto are also provided, including for example for the detection, prevention, and/or therapeutical treatment of CD33-related diseases, in particular, leukemias such as AML.



traducir


 

COMPOSITION FOR PREVENTING AND TREATING HEMANGIOMA OR LYMPHOMA AND PREPARATION METHOD AND USE THEREOF

NºPublicación: WO2018196537A1 01/11/2018

Solicitante:
PLUSONE CO LTD [CN]

Resumen de: WO2018196537A1

Disclosed is a composition for preventing and treating hemangioma or lymphoma, comprising 0.31-0.94 part by weight of ginsenoside Rb2, 1 part by weight of ginsenoside Rg3, and 0.63-1 part by weight of ginsenoside Rg5. The composition can inhibit the growth and/or proliferation of hemangioma cells or lymphoma cells.



traducir


 

METHODS, AGENTS, AND COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

NºPublicación: WO2018200041A1 01/11/2018

Solicitante:
UNIV CINCINNATI [US]

Resumen de: WO2018200041A1

A method of treating a subject suffering from a condition characterized by over- expression of Ten-eleven translocation 1 (TET1) is provided, the method including administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, having the Formula I: (formula I) wherein: R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, hydroxyl, alkyl, alkoxy, amine, halo, and trifluoromethyl, and wherein any two adjacent moieties of R1, R2, R3, R4, and R5 may come together to form a heterocyclic ring; R6 is H or hydroxyl; and R7 is selected from H, (formula 2), and (formula 3), wherein R8 is C or O. Also provided are methods for selectively suppressing transcription of TET1 and/or reducing a level of 5-hydroxymethylcytosine in a subject by administering an effective amount of a Formula (I) compound and pharmaceutical compositions comprising Formula (I) compounds.



traducir


 

METHODS OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH FARNESYLTRANSFERASE INHIBITORS

NºPublicación: AU2018241132A1 01/11/2018

Solicitante:
VERIDEX LLC

Resumen de: AU2018241132A1

Abstract The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less instrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGR-P1 :APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (RI 15777, ZARNESTRA@) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.



traducir


 

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

NºPublicación: US2018312474A1 01/11/2018

Solicitante:
IMAGO BIOSCIENCES INC [US]

Resumen de: US2018312474A1

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.



traducir


 

SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS

NºPublicación: US2018312485A1 01/11/2018

Solicitante:
UNIV VANDERBILT [US]

Resumen de: US2018312485A1

The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.



traducir


 

Hypomethylation of TET2 target genes for identifying a curable subgroup of acute myeloid leukemia

NºPublicación: US2018312927A1 01/11/2018

Solicitante:
UNIV TEMPLE [US]

Resumen de: US2018312927A1

The invention provides AML-specific methylation biomarkers (SP140, MCCC1, EHMT1 and MTSS1). In one embodiment, a biomarker is differentially methylated, specifically in AML.



traducir


 

EZH2 INHIBITORS FOR TREATING LYMPHOMA

NºPublicación: US2018311251A1 01/11/2018

Solicitante:
EPIZYME INC

Resumen de: US2018311251A1

The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.



traducir


 

Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

NºPublicación: US2018311330A1 01/11/2018

Solicitante:
IMMATICS BIOTECHNOLOGIES GMBH [DE]

Resumen de: US2018311330A1

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.



traducir


 

METHODS OF TREATING MYELOID LEUKEMIA

NºPublicación: US2018311308A1 01/11/2018

Solicitante:
BIOKINE THERAPEUTICS LTD [IL]
BIOLINERX LTD [IL]

Resumen de: US2018311308A1

There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a CXCR4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent.



traducir


 

Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer

NºPublicación: AU2017249078A1 01/11/2018

Solicitante:
LILLY CO ELI

Resumen de: AU2017249078A1

Medicaments for use in treating acute myelogenous leukemia, chronic myelogenous leukemia, breast cancer, ovarian cancer, malignant melanoma, lung cancer, pancreatic cancer, glioblastoma, sarcoma, desmoid tumors, adenoid cystic carcinoma (ACC), colorectal cancer, prostate cancer, or medulloblastoma in a patient by administering simultaneously, separately, or sequentialy, 4,4,4-trifluoro-N-[(IS)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof, and N-[5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof.



traducir


 

Combination therapy with notch and PI3K/mTOR inhibitors for use in treating cancer

NºPublicación: AU2017249988A1 01/11/2018

Solicitante:
LILLY CO ELI

Resumen de: AU2017249988A1

Medicaments for use in treating T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, breast cancer, ovarian cancer, melanoma, lung cancer, pancreatic cancer, glioblastoma, sarcoma, desmoid tumors, adenoid cystic carcinoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, or skin cancer in a patient comprising combination therapy with 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]butanamide, or a phamlaceutically acceptable salt or hydrate thereof, and 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof.



traducir


 

CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF CONDENSED AZACYCLES (CANNABINOID RECEPTOR MODULATORS)

NºPublicación: EP3395812A1 31/10/2018

Solicitante:
ARENA PHARM INC [US]

Resumen de: EP3395812A1

The present invention relates to crystalline forms of (1a S ,5a S )-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1 H -2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (( S )-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (Compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB 2 receptor and are therefore useful in the treatment of CB 2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation for example; atherosclerosis; undesired immune cell activity, and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, Behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis; and Parkinson's disease.



traducir


 

ANTIBODY AGENTS SPECIFIC FOR HUMAN CD19 AND USES THEREOF

NºPublicación: PH12018500810A1 29/10/2018

Solicitante:
EUREKA THERAPEUTICS INC [US]

Resumen de: PH12018500810A1

Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.



traducir


 

PHARMACEUTICAL COMPOSITION FOR USE IN TREATING AML AND METHOD OF TREATING AML IN A SUBJECT IN NEED THEREOF

Nº publicación: US2018303812A1 25/10/2018

Solicitante:
DAIICHI SANKYO CO LTD [JP]
UNIV TEXAS [US]

Resumen de: US2018303812A1

The present invention provides a pharmaceutical composition for use in treating acute myeloid leukemia (AML) and a method of treating AML in a patient in need thereof. The present invention also provides a method for predicting the sensitivity to the treatment in the patient using gene expression signature.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver